Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Gross Margin (2020 - 2026)

Gyre Therapeutics has reported Gross Margin over the past 6 years, most recently at 35.97% for Q4 2025.

  • Quarterly Gross Margin fell 5981.0% to 35.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 76.42% through Dec 2025, down 1991.0% year-over-year, with the annual reading at 44.09% for FY2025, 5223.0% down from the prior year.
  • Gross Margin was 35.97% for Q4 2025 at Gyre Therapeutics, down from 94.67% in the prior quarter.
  • Over five years, Gross Margin peaked at 96.95% in Q2 2024 and troughed at 0.89% in Q1 2021.
  • The 5-year median for Gross Margin is 95.59% (2025), against an average of 65.79%.
  • Year-over-year, Gross Margin plummeted -10057bps in 2021 and then skyrocketed 9664bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 0.57% in 2021, then surged by 16843bps to 96.06% in 2022, then fell by -1bps to 95.4% in 2023, then grew by 0bps to 95.78% in 2024, then plummeted by -62bps to 35.97% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Gross Margin are 35.97% (Q4 2025), 94.67% (Q3 2025), and 95.7% (Q2 2025).